Publications by authors named "Hannah Eeckhaut"
Article Synopsis
- Komagataella phaffii, formerly known as Pichia pastoris, is widely used for producing recombinant proteins for therapeutics and food, but the original strain NRRL Y-11430 is restricted.
- Researchers identified the NCYC 2543 strain from 1954 as a foundation for developing an open-access strain called OPENPichia, designed to enable widespread use without restrictions.
- By modifying the HOC1 gene in NCYC 2543, the team enhanced its ability to take up DNA and improve protein secretion, providing a genome-sequenced strain and a versatile expression vector toolkit for the biotech community.
Article Synopsis
- SARS-CoV-2-neutralizing antibodies (nABs) have shown potential in COVID-19 treatment, but resistant strains have made most existing nABs ineffective, highlighting the need for new cocktails targeting distinct epitopes.
- A discovery program used traditional methods combined with AI predictions to identify two potent nABs, which were validated through animal testing.
- However, structural analysis revealed that the AI predictions were flawed, as both nABs targeted the same binding epitope, emphasizing that experimental validation is crucial in selecting effective nABs.
While transcriptome- and proteome-wide technologies to assess processes in protein biogenesis are now widely available, we still lack global approaches to assay post-ribosomal biogenesis events, in particular those occurring in the eukaryotic secretory system. We here develop a method, SECRiFY, to simultaneously assess the secretability of >10 protein fragments by two yeast species, S. cerevisiae and P.
View Article and Find Full Text PDFBroadly neutralizing antibodies are an important treatment for individuals with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody-based therapeutics are also essential for pandemic preparedness against future outbreaks. Camelid-derived single domain antibodies (VHHs) exhibit potent antimicrobial activity and are being developed as SARS-CoV-2–neutralizing antibody-like therapeutics.
View Article and Find Full Text PDF